Histone deacetylase inhibitors reduce polyglutamine toxicity - Wikidata - awgldk - TriplyDB

Histone deacetylase inhibitors reduce polyglutamine toxicity

Histone deacetylase inhibitors reduce polyglutamine toxicity

http://www.wikidata.org/entity/Q33953013

about

Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans Ataxin 1, a SCA1 neurodegenerative disorder protein, is functionally linked to the silencing mediator of retinoid and thyroid hormone receptors Live-cell imaging reveals divergent intracellular dynamics of polyglutamine disease proteins and supports a sequestration model of pathogenesis.Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau Androgen-dependent pathology demonstrates myopathic contribution to the Kennedy disease phenotype in a mouse knock-in model Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases Pathogenic mechanisms and therapeutic strategies in spinobulbar muscular atrophy Developing treatment for spinal and bulbar muscular atrophy Epigenetic mechanisms of neurodegeneration in Huntington's disease Histone acetylation, acetyltransferases, and ataxia--alteration of histone acetylation and chromatin dynamics is implicated in the pathogenesis of polyglutamine-expansion disorders Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein Proteome analysis of soluble nuclear proteins reveals that HMGB1/2 suppress genotoxic stress in polyglutamine diseases.Genetic knock-down of HDAC7 does not ameliorate disease pathogenesis in the R6/2 mouse model of Huntington's disease Histone H4 deacetylation plays a critical role in early gene silencing during neuronal apoptosis Animal models of Kennedy disease.Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease.Dysregulation of upstream binding factor-1 acetylation at K352 is linked to impaired ribosomal DNA transcription in Huntington's disease.Deregulation of HDAC1 by p25/Cdk5 in neurotoxicity Differentiation of NUT midline carcinoma by epigenomic reprogramming.Assessing the contribution of heterogeneous distributions of oligomers to aggregation mechanisms of polyglutamine peptides Polyglutamine fibrillogenesis: the pathway unfolds Sodium valproate alleviates neurodegeneration in SCA3/MJD via suppressing apoptosis and rescuing the hypoacetylation levels of histone H3 and H4 Modulation of acetylation: creating a pro-survival and anti-inflammatory phenotype in lethal hemorrhagic and septic shock.Proceedings of the fourth international conference on central hypoventilation.Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases.Protein aggregation in motor neurone disorders.Experimental therapeutics in transgenic mouse models of Huntington's disease.Kennedy's disease: pathogenesis and clinical approaches.Aberrant histone acetylation, altered transcription, and retinal degeneration in a Drosophila model of polyglutamine disease are rescued by CREB-binding protein HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis.The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.Novel therapeutic targets for Huntington's disease.Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.Implication of abnormal epigenetic patterns for human diseases.X-linked mental retardation and epigenetics.Acetate reduces PGE2 release and modulates phospholipase and cyclooxygenase levels in neuroglia stimulated with lipopolysaccharide Creating a pro-survival and anti-inflammatory phenotype by modulation of acetylation in models of hemorrhagic and septic shock.

P2860

Q21144448-955639C5-5091-41DA-8102-C85033186A79 Q24316293-B0717809-3D75-4314-A2A6-8D7C71E26D03 Q24534867-00E37E65-E23A-4AFD-B038-500AB613FBFF Q24651880-08B98DAD-CFA4-4949-95BB-B308C0040DF7 Q24673304-31CF203F-070D-43EC-BA6D-813AF5C2CB56 Q26771812-4E771222-413D-452F-ADB3-85EE8E53D881 Q27007098-183D1E80-642E-4CDC-865E-969543C1D37A Q27008808-43AAB63E-7EC0-40BB-9C5B-5370D7860FA0 Q28297936-6794F23B-18F9-4E69-A1D1-CF4006BDBB8E Q30433574-47273493-597D-4723-85FB-18E246FCCB5F Q30445140-5AF4F29B-E066-472B-9A61-00AB3ED7D834 Q33279931-C7DA6B7C-3198-489F-BADA-D7360B004494 Q33457171-15DCDD9E-822F-4772-AE48-0A5BB955D3B5 Q33588162-AFC0E012-20A6-4A33-BE25-639D3BF172A3 Q33844742-5FC8180D-0321-4F48-835E-346BA5DCF2AE Q33911613-596FA31C-BBA6-49C4-BAD6-4CB15902ECB3 Q34026790-1B3E527C-B9F6-4243-BB71-21FC545550BF Q34028507-DA4D4BDD-90E9-41C2-A29C-806F28540C3C Q34174143-59E757C0-F9D0-4683-87FC-E0BA149B1C39 Q34181169-AC555DF2-C517-4543-81E0-C36383ADABAC Q34466014-914C1D65-FA52-4D4E-B209-CE27FBFF5E79 Q34575681-F38BA0FA-C0DC-4740-A9B4-D6D80A2F011D Q34635234-4B118590-D472-4304-8E67-711EE6FC5517 Q34721441-47F79F7F-8CEA-44A6-8EE2-26BD4A5095BF Q34763178-78E6CF08-D214-4F8E-A644-BFDF791CC68A Q34923735-175A49EA-0DD4-46B0-9B56-42913D319099 Q35095142-BBC56A83-BEA1-4CF5-AA4C-5A939A63C381 Q35592405-606DC639-B22D-4394-B06A-B0C46DE2C71A Q35752429-6D488D48-B72A-453B-854E-5B7FD5DE3CEA Q35777504-F4DEC1BE-5633-4E94-871E-A626522F7A27 Q35965543-D74F6885-A471-4ED6-ADD3-A9A76D35181E Q35968237-2349660C-37CB-4BAF-AC42-6657A9355DCF Q36045254-861E6602-767A-4C3B-BE26-C8848A781E92 Q36219680-95BDBAAD-DEC8-408E-9C37-973B321DCDF2 Q36482299-87D09947-B333-4AFB-9B91-D0CA6346B6A5 Q36598779-83666467-54CD-44B2-B868-3C6323DC96D2 Q36626596-F535DEE4-FCF2-4900-AE84-AFC1161F9F3E Q36663018-12F9AB81-D81C-4C03-A4EC-1A7354CA9862 Q36951565-5A7405A7-2C2D-423E-B71E-9DEBB545D555 Q36972324-9D8010B6-EA8C-4225-B092-32DCF5F841DB

P2860

Histone deacetylase inhibitors reduce polyglutamine toxicity

http://www.wikidata.org/entity/Q33953013

description

2001 nî lūn-bûn

@nan

2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Histone deacetylase inhibitors reduce polyglutamine toxicity

@ast

Histone deacetylase inhibitors reduce polyglutamine toxicity

@en

type

label

Histone deacetylase inhibitors reduce polyglutamine toxicity

@ast

Histone deacetylase inhibitors reduce polyglutamine toxicity

@en

prefLabel

Histone deacetylase inhibitors reduce polyglutamine toxicity

@ast

Histone deacetylase inhibitors reduce polyglutamine toxicity

@en

P1433

Q33953013-4F44C01C-473B-4CF4-899E-E4E61C0CF6F0

P1476

Q33953013-BEACA22C-5B50-46BA-94AF-6EC5CA2BE58D

P2093

Q33953013-142785AE-ACE3-47C9-BCB9-9B65875A7DEE

Q33953013-463E6D43-C692-4BCA-86E7-A7F87070BB30

Q33953013-49928EA3-EF4E-46A4-98D9-F89BA165193F

Q33953013-95D135E9-2A2A-413A-940E-2DC77AEEE6A1

Q33953013-CF4F0759-37DC-40A3-B17F-F84F7DA4FC97

Q33953013-D5718DA1-1C81-4522-AB88-A7507841ECCB

P2860

Q33953013-063C24EC-57ED-4B0D-90B7-44455AFD48AB

Q33953013-08F629B0-959C-49FE-BAA5-D80985CE5ABA

Q33953013-155317C5-0A64-4A37-8645-0CA77B795C82

Q33953013-15E3AB49-5C5E-41CE-AD5F-9E1FEB49F922

Q33953013-1B08B832-6BAC-4E8F-B1F4-5F81AEDFE5F4

Q33953013-1E1BF5B9-CDF1-4F61-A93F-93CCE770CF1C

Q33953013-21F4283F-2F30-4443-AFC3-117F34CE96F8

Q33953013-2699B819-626C-4632-873A-4BE953DB51AA

Q33953013-2772DC89-91CC-499C-B593-39F833D97555

Q33953013-2A633800-1CA3-4868-A0F3-225DA519211D

P304

Q33953013-CC74DB36-7E90-48C4-8316-A48CA9CBCAB0

P31

Q33953013-7535825E-A670-45E4-8A08-35F9ACA4F264

P356

Q33953013-E9FC5CC2-7BF3-4D19-88B2-5C17DBA30A25

P407

Q33953013-B05249A6-C0A5-4EFC-9DF1-9D29FCEF8815

P433

Q33953013-C4D5C2D6-8C25-4CFC-A14E-B4BD4DF48496

P478

Q33953013-D8CD28AF-260F-47DA-A1C3-525067D351CF

P577

Q33953013-0132AC2E-70E0-425C-87D1-69D4845A7B85

P5875

Q33953013-8BFA8F99-E7B2-4B11-9DFE-32758AED88EA

P698

Q33953013-43CB6564-4278-4B30-A403-592812BFC71E

P932

Q33953013-1651559C-8A1A-44B0-B759-2CE231A0D081

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Histone deacetylase inhibitors reduce polyglutamine toxicity

@en

P2093

A A Taye

http://www.w3.org/2001/XMLSchema#string

A McCampbell

http://www.w3.org/2001/XMLSchema#string

E Penney

http://www.w3.org/2001/XMLSchema#string

J S Steffan

http://www.w3.org/2001/XMLSchema#string

K H Fischbeck

http://www.w3.org/2001/XMLSchema#string

L Whitty

http://www.w3.org/2001/XMLSchema#string

P2860

Nuclear localization of the spinocerebellar ataxia type 7 protein, ataxin-7

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription

Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures

CREB-binding protein in androgen receptor-mediated signaling

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone

Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin

CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1

Recruitment of p300/CBP in p53-dependent signal pathways

Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation

P304

15179-15184

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.261400698

http://www.w3.org/2001/XMLSchema#string

P407

P433

26

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11614829

http://www.w3.org/2001/XMLSchema#string

P698

11742087

http://www.w3.org/2001/XMLSchema#string

P932

65003

http://www.w3.org/2001/XMLSchema#string